Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

35.99
-1.0400-2.81%
Pre-market: 36.180.1868+0.52%08:00 EST
Volume:1.18M
Turnover:42.13M
Market Cap:2.84B
PE:94.61
High:37.57
Open:37.16
Low:34.98
Close:37.03
52wk High:50.71
52wk Low:22.61
Shares:79.05M
Float Shares:78.23M
Volume Ratio:1.23
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3804
EPS(LYR):0.3100
ROE:2.49%
ROA:2.43%
PB:2.26
PE(LYR):116.10

Loading ...

Veracyte Inc. kündigt Veröffentlichung neuer Finanzergebnisse an

Reuters
·
Feb 05

Press Release: Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Dow Jones
·
Feb 05

Exploring US High Growth Tech Stocks In February 2026

Simply Wall St.
·
Feb 03

Assessing Veracyte (VCYT) Valuation As Recent Momentum Meets An Expensive P/E Ratio

Simply Wall St.
·
Jan 22

A Look At Veracyte (VCYT) Valuation After Strong 2025 Update And 2026 Growth Guidance

Simply Wall St.
·
Jan 14

Veracyte: Strong Near-Term Performance but Execution and Valuation Risks Justify Sell Rating

TIPRANKS
·
Jan 13

Veracyte reports preliminary Q4 revenue $138M-$140M, consensus $131.75M

TIPRANKS
·
Jan 12

Veracyte sees FY26 revenue $570M-$582M, consensus $565.76M

TIPRANKS
·
Jan 12

BRIEF-Veracyte Outlook FY Revenue Growth 16%

Reuters
·
Jan 12

Veracyte Projects 2026 Revenue Growth of Up to 13% and Adjusted EBITDA Margin of 25%

Reuters
·
Jan 12

Veracyte Outlook FY Revenue USD 515-517 Million

THOMSON REUTERS
·
Jan 12

Press Release: Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Dow Jones
·
Jan 12

Veracyte Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 06

Veracyte to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 30, 2025

Veracyte SVP and General Counsel Annie McGuire Reports Disposal of Common Shares

Reuters
·
Dec 18, 2025

Veracyte SVP and General Counsel Annie McGuire Reports Disposal of Common Shares

Reuters
·
Dec 05, 2025

Veracyte CFO Rebecca Chambers Reports Disposal of Common Shares

Reuters
·
Dec 05, 2025

Veracyte Is Maintained at Underweight by Morgan Stanley

Dow Jones
·
Dec 03, 2025

Morgan Stanley Raises Price Target on Veracyte to $48 From $40, Keeps Underweight Rating

MT Newswires Live
·
Dec 02, 2025

Veracyte Inc. Director Evan Jones Reports Sale of Common Shares

Reuters
·
Nov 27, 2025